Common stock, $0.001 par value
- Symbol
- CTXR
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Citius Pharmaceuticals, Inc.
CTXRNASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events. On August 5, 2026, our wholly-owned subsidiary, Citius Oncology, Inc., issued a press release announcing an update on the expanding base of institutional accounts ordering LYMPHIR®. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No.…
Press release in this filing
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment →Company context
Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I - III CTCL after at least one prior systemic therapy. Management estimates the initial CTCL market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets, and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology’s competitive positioning. For more information, please visit www.citiusonc.com.
Current securities
Historical securities (1)
Recent company filings
- Results of Operations and Financial ConditionOct 26, 2026
- Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingAug 21, 2026
- 10-Q filingAug 14, 2026
- Results of Operations and Financial ConditionAug 14, 2026
- SCHEDULE 13G/A - filed by CVI Investments, Inc. regarding Citius Pharmaceuticals, Inc.Aug 14, 2026
Registered securities in this filing
Citius Pharmaceuticals, Inc. · 8-K · Filed 2026-08-05
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On August 5, 2026, our wholly-owned
subsidiary, Citius Oncology, Inc., issued a press release announcing an update on the expanding base of institutional accounts ordering
LYMPHIR®. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
99.1 Press release, dated August 5, 2026.
104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).
Filed exhibits (1)
EX-99.1 2 ea030037301ex99-1.htm PRESS RELEASE, DATED AUGUST 5, 2026 Exhibit 99.1 Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment New institutional accounts ordering LYMPHIR increased 78% quarter over quarter LYMPHIR’s near-universal payer coverage expands market access Initial cutaneous T-cell lymphoma (CTCL) market for LYMPHIR currently exceeds $400 million CRANFORD, N.J., August 5, 2026 - Citius Oncology, Inc. (“Citius Oncology”) (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. (“Citius Pharma”) (Nasdaq: CTXR), today provided an update on the expanding base of institutions ordering LYMPHIR® (denileukin diftitox-cxdl) through wholesalers, continued formulary progress at priority U.S. treatment centers, and other key indicators supporting the product’s commercial launch. “Our commercial progress is reflected in two closely connected measures: growth in the number of institutions ordering LYMPHIR and continued expansion of the formulary approvals that enable additional institutions to begin ordering the product and treating patients,” said Leonard Mazur, Chairman and Chi…
Open exhibit ↗